The Targeted Therapy Panel (50 genes) is a comprehensive genetic test designed to analyze mutations across 50 clinically relevant genes associated with cancer. By identifying specific genetic alterations, this panel helps doctors determine whether a patient may benefit from targeted therapies, which are more precise than conventional treatments. It is particularly useful in guiding personalized cancer care, improving treatment outcomes, and avoiding unnecessary therapies by tailoring interventions to the patient’s unique genetic profile.
A positive result indicates actionable mutations, and doctors may recommend targeted therapies or clinical trials tailored to those genetic changes.
A negative result means no actionable mutations were detected, and standard treatments may be considered instead.
The panel covers multiple cancers, including lung, breast, colorectal, ovarian, and hematological malignancies, where targeted therapies are available.
Patients diagnosed with cancer, especially those with advanced or recurrent disease, are recommended for this test to explore targeted therapy options.
It helps identify actionable mutations, allowing doctors to prescribe therapies tailored to a patient’s genetic profile, improving treatment outcomes and reducing unnecessary side effects.
No, current medications do not alter genetic mutations. However, inform your doctor about ongoing treatments for accurate interpretation.
Doctors may repeat the test if cancer progresses or recurs, as new mutations can develop over time.
...
Didn't recieved OTP Yet? Resend OTP